See the DrugPatentWatch profile for Jornay
When Does the Patent for Jornay PM Expire?
The primary patent protecting Jornay PM, known as U.S. Patent No. 11,529,376, is slated to expire on August 18, 2040. [1] This patent covers aspects of the drug's formulation and method of use. [1]
What Other Patents Protect Jornay PM?
In addition to U.S. Patent No. 11,529,376, there are other patents related to Jornay PM. These may cover different aspects of the drug's development, manufacturing, or specific uses. Information on these additional patents can be found on DrugPatentWatch.com. [2]
How Does Patent Expiration Affect Drug Availability?
When a drug's primary patents expire, it typically opens the door for generic or biosimilar manufacturers to seek regulatory approval and market their versions of the medication. This can lead to increased competition and potentially lower prices for consumers. [3]
What Are the Key Components of Jornay PM?
Jornay PM is a methylphenidate hydrochloride extended-release capsule used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). [4] It utilizes a novel delayed-release, sprinkleable capsule formulation. [4] The drug is designed to provide a biphasic release of methylphenidate, with an initial release in the morning and a second release in the afternoon. [4] This extended-release profile is achieved through a pH-dependent coating and a lipid matrix. [4]
Who Manufactures Jornay PM?
Jornay PM is manufactured by Ironshore Pharmaceuticals. [5]
What is the Brand Name for Methylphenidate Hydrochloride Extended-Release Capsules?
Jornay PM is the brand name for methylphenidate hydrochloride extended-release capsules. [4]
---
Sources:
[1] DrugPatentWatch.com - Jornay PM Patent Expiration Date.
[2] DrugPatentWatch.com
[3] U.S. Food & Drug Administration. (2018). Generic Drugs: Questions and Answers.
[4] Ironshore Pharmaceuticals. (n.d.). Jornay PM Prescribing Information.
[5] Ironshore Pharmaceuticals. (n.d.). Our Products.